Journal
IMMUNOLOGICAL REVIEWS
Volume 239, Issue -, Pages 85-98Publisher
WILEY
DOI: 10.1111/j.1600-065X.2010.00966.x
Keywords
cervical cancer; NKT cells; papillomavirus infection; immunosuppression; immunoregulation
Categories
Funding
- National Health and Medical Research Council [351439]
- NIH [1 U01 CA141583-01]
- Cancer Council Australia
- Cancer Research Institute (New York)
- Lions Medical Research Foundation
- Australian Cancer Research Foundation
- Queensland Government
- NATIONAL CANCER INSTITUTE [U01CA141583] Funding Source: NIH RePORTER
Ask authors/readers for more resources
The recent development of vaccines prophylactic against human papillomavirus (HPV) infection has the potential to reduce the incidence of cervical cancer globally by up to 70% over the next 40 years, if universal immunization is adopted. As these prophylactic vaccines do not alter the natural history of established HPV infection, immunotherapies to treat persistent HPV infection and associated precancers would be of benefit to assist with cervical cancer control. Efforts to develop immuno-therapeutic vaccines have been hampered by the relative non-immunogenicity of HPV infection, by immunoregulatory processes in skin, and by subversion of immune response induction and immune effector functions by papillomavirus proteins. This review describes HPV-specific immune responses induced by viral proteins, their regulation by host and viral factors, and highlights some conclusions from our own recent research.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available